Literature DB >> 23917314

Rapid emergence of resistance to linezolid and mutator phenotypes in Staphylococcus aureus isolates from an adult cystic fibrosis patient.

Asmaa Tazi1, Jeanne Chapron, Gerald Touak, Magalie Longo, Dominique Hubert, Gislène Collobert, Daniel Dusser, Claire Poyart, Philippe C Morand.   

Abstract

Linezolid has emerged as an important therapeutic option for the treatment of Staphylococcus aureus in patients with cystic fibrosis. We report the rapid emergence, upon treatment with linezolid, of linezolid-resistant S. aureus clinical isolates through the accumulation of resistance-associated 23S rRNA mutations, together with acquisition of an altered mutator phenotype.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23917314      PMCID： PMC3811410          DOI： 10.1128/AAC.01392-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  22 in total

1.  Linezolid resistance in clinical isolates of Staphylococcus aureus.

Authors:  Peter Wilson; J A Andrews; R Charlesworth; R Walesby; M Singer; D J Farrell; M Robbins
Journal:  J Antimicrob Chemother       Date:  2003-01       Impact factor: 5.790

2.  Linezolid resistance in a clinical isolate of Staphylococcus aureus.

Authors:  S Tsiodras; H S Gold; G Sakoulas; G M Eliopoulos; C Wennersten; L Venkataraman; R C Moellering; M J Ferraro
Journal:  Lancet       Date:  2001-07-21       Impact factor: 79.321

3.  Role of mutS and mutL genes in hypermutability and recombination in Staphylococcus aureus.

Authors:  Anne-Laure Prunier; Roland Leclercq
Journal:  J Bacteriol       Date:  2005-05       Impact factor: 3.490

4.  Pulsed-field gel electrophoresis as a replacement for bacteriophage typing of Staphylococcus aureus.

Authors:  T L Bannerman; G A Hancock; F C Tenover; J M Miller
Journal:  J Clin Microbiol       Date:  1995-03       Impact factor: 5.948

5.  Serum and sputum concentrations following the oral administration of linezolid in adult patients with cystic fibrosis.

Authors:  Dinesh Saralaya; Daniel G Peckham; Bill Hulme; Caroline M Tobin; Miles Denton; Steve Conway; Christine Etherington
Journal:  J Antimicrob Chemother       Date:  2004-01-16       Impact factor: 5.790

6.  Linezolid resistance in Staphylococcus aureus: characterization and stability of resistant phenotype.

Authors:  Satish K Pillai; George Sakoulas; Christine Wennersten; George M Eliopoulos; Robert C Moellering; Mary Jane Ferraro; Howard S Gold
Journal:  J Infect Dis       Date:  2002-11-04       Impact factor: 5.226

7.  Reversion to susceptibility in a linezolid-resistant clinical isolate of Staphylococcus aureus.

Authors:  Venkata G Meka; Howard S Gold; Amy Cooke; Lata Venkataraman; George M Eliopoulos; Robert C Moellering; Stephen G Jenkins
Journal:  J Antimicrob Chemother       Date:  2004-09-03       Impact factor: 5.790

8.  High rate of macrolide resistance in Staphylococcus aureus strains from patients with cystic fibrosis reveals high proportions of hypermutable strains.

Authors:  Anne-Laure Prunier; Brigitte Malbruny; Muriel Laurans; Jacques Brouard; Jean-François Duhamel; Roland Leclercq
Journal:  J Infect Dis       Date:  2003-05-15       Impact factor: 5.226

9.  Linezolid pharmacokinetics in adult patients with cystic fibrosis.

Authors:  John A Bosso; Patrick A Flume; Susan L Gray
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

Review 10.  The emerging problem of linezolid-resistant Staphylococcus.

Authors:  Bing Gu; Theodoros Kelesidis; Sotirios Tsiodras; Janet Hindler; Romney M Humphries
Journal:  J Antimicrob Chemother       Date:  2012-09-04       Impact factor: 5.758
View more
  6 in total

1.  Pharmacokinetics of Telavancin in Adult Patients with Cystic Fibrosis during Acute Pulmonary Exacerbation.

Authors:  James M Kidd; Colleen M Sakon; Louise-Marie Oleksiuk; Jeffrey J Cies; Rebecca S Pettit; David P Nicolau; Joseph L Kuti
Journal:  Antimicrob Agents Chemother       Date:  2019-12-20       Impact factor: 5.191

2.  Emergence and Within-Host Genetic Evolution of Methicillin-Resistant Staphylococcus aureus Resistant to Linezolid in a Cystic Fibrosis Patient.

Authors:  Caroline Rouard; Fabien Garnier; Jeremy Leraut; Margaux Lepainteur; Lalaina Rahajamananav; Jeanne Languepin; Marie-Cécile Ploy; Nadège Bourgeois-Nicolaos; Florence Doucet-Populaire
Journal:  Antimicrob Agents Chemother       Date:  2018-11-26       Impact factor: 5.191

3.  Emergence of cfr-Mediated Linezolid Resistance in a Methicillin-Resistant Staphylococcus aureus Epidemic Clone Isolated from Patients with Cystic Fibrosis.

Authors:  Juan de Dios Caballero; María Dolores Pastor; Ana Vindel; Luis Máiz; Genoveva Yagüe; Carme Salvador; Marta Cobo; María-Isabel Morosini; Rosa del Campo; Rafael Cantón
Journal:  Antimicrob Agents Chemother       Date:  2015-12-14       Impact factor: 5.191

4.  In-Host Emergence of Linezolid Resistance in a Complex Pattern of Toxic Shock Syndrome Toxin-1-Positive Methicillin-Resistant Staphylococcus aureus Colonization in Siblings with Cystic Fibrosis.

Authors:  Agathe Boudet; Alexandre Jay; Catherine Dunyach-Remy; Raphaël Chiron; Jean-Philippe Lavigne; Hélène Marchandin
Journal:  Toxins (Basel)       Date:  2021-04-28       Impact factor: 4.546

5.  Tedizolid Phosphate: a Next-Generation Oxazolidinone.

Authors:  Jeffrey M Rybak; Karrine Roberts
Journal:  Infect Dis Ther       Date:  2015-02-24

6.  Australian propolis ethanol extract exerts antibacterial activity against methicillin-resistant Staphylococcus aureus by mechanisms of disrupting cell structure, reversing resistance, and resisting biofilm.

Authors:  Fei Wang; Hui Liu; Junya Li; Wenwen Zhang; Bin Jiang; Hongzhuan Xuan
Journal:  Braz J Microbiol       Date:  2021-07-07       Impact factor: 2.214
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.